Ultime notizie per MiNK Therapeutics (NASDAQ:INKT) Azioni

MiNK Therapeutics

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

MiNK Therapeutics Inc

Earnings

News

TRIP

CORRECTION: TripAdvisor Q3 2024 Adj. EPS $0.50 Beats $0.44 Estimate, Sales $371.000M Miss $527.903M Estimate

Earnings Beats

Earnings Misses

American States Water Q3 2024 GAAP EPS $0.95 Misses $0.97 Estimate, Sales $161.782M Beat $161.000M Estimate

Tanger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKT#NYSE">SKT</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.53 by 1.89 percent. This is a 8 percent increase over earnings of $0.50 per share from the same period last year. The company reported quarterly sales of $133.00 million which beat the analyst consensus estimate of $124.70 million by 6.66 percent. This is a 13.34 percent increase over sales of $117.35 million the same period last year.

Tanger Q3 FFO $0.54 Beats $0.53 Estimate, Sales $133.00M Beat $124.70M Estimate

Grand Canyon Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) raises FY2024 Adj EPS guidance from $7.85-8.04 to $8.02-8.05 vs $7.99 analyst estimate. Narrows FY2024 sales outlook from $1.03 billion-1.03 billion to $1.03 billion-1.03 billion vs $1.03 billion estimate.

Guidance

LOPE

Grand Canyon Education Raises FY2024 Adj EPS Guidance from $7.85-8.04 to $8.02-8.05 vs $7.99 Est; Narrows FY2024 Sales Guidance from $1.03B-1.03B to $1.03B-1.03B vs $1.03B Est

Beyond Meat Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) reported third-quarter financial results Wednesday after the bell. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/11/g41786618/beyond-meat-reports-third-quarter-2024-financial-results">rundown of the report</a>.
Q3 Earnings: Beyond Meat reported third-quarter revenue of $81.01 million, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $80.71 million, according to&nbsp;<a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.&nbsp;The&nbsp;plant-based meat&nbsp;company reported a third-quarter adjusted loss of 41 cents per share, beating estimates for a loss of 44 cents per share.
Total revenues increased 7.6% on a year-over-year basis. U.S. retail channel net revenues increased&nbsp;14.6% year-over-year and U.S. foodservice channel net revenues increased&nbsp;15.5%. International retail channel net revenues jumped 17% year-over-year while international foodservice channel net revenues fell 17.2%.
Beyond Meat ended the quarter with $134.9 million in cash, cash equivalents and restricted cash. The company had total outstanding debt of $1.1 billion as of Sept. 28.
&#8220;We are pleased to report that in the third quarter, we returned to growth, increasing net revenues on a year-over-year basis, while continuing to expand gross margin and reduce operating expenses on both a sequential and year-over-year basis,&#8221; said Ethan Brown, president and CEO of Beyond Meat.
&#8220;Looking ahead, we expect to increase our cash reserves by year-end and pursue further balance sheet restructuring in 2025.&#8221;
Outlook:&nbsp;Beyond Meat revised its full-year 2024 revenue outlook from a range of $320 million to $340 million to a new range of $320 million to $330 million. Analysts are anticipating full-year revenue of $328.59 million, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Management will further discuss the company&#8217;s quarterly results on a conference call slated for 5 p.m. ET.
BYND Price Action: <a href="https://www.benzinga.com/quote/BYND" target="_blank" rel="noreferrer noopener">Beyond Meat shares</a> were down 5.78% after hours at $6.20 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Don&#8217;t Miss: • <a href="https://www.benzinga.com/general/politics/24/11/41745522/trump-or-harris-as-mcdonalds-managers-benzinga-readers-would-rather-have-this-candidate-as-their">Trump Or Harris As McDonald&#8217;s Managers? Benzinga Readers Would Rather Have This Candidate As Their Boss At The Restaurant</a>
Photo: Courtesy of Beyond Meat.

Movers

BYND

Beyond Meat Returns To Growth In Q3: Revenue Beat, EPS Beat, Cash Reserves In Focus

F&amp;G Annuities &amp; Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FG#NYSE">FG</a>) reported quarterly earnings of $1.22 per share which beat the analyst consensus estimate of $1.09 by 11.93 percent. The company reported quarterly sales of $2.39 billion which beat the analyst consensus estimate of $1.22 billion by 95.09 percent. This is a 180.38 percent increase over sales of $851.00 million the same period last year.

F&G Annuities & Life Q3 2024 Adj EPS $1.22 Beats $1.09 Estimate, Sales $2.39B Beat $1.22B Estimate

Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.30) by 63.33 percent. The company reported quarterly sales of $2.326 billion which missed the analyst consensus estimate of $2.697 billion by 13.76 percent. This is a 10.19 percent decrease over sales of $2.590 billion the same period last year.

CTVA

Corteva Q3 2024 Adj. EPS $(0.49) Misses $(0.30) Estimate, Sales $2.326B Miss $2.697B Estimate

Grand Canyon Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) narrows FY2024 GAAP EPS guidance from $7.63-7.81 to $7.76-7.79 vs $7.73 analyst estimate..

Grand Canyon Education Narrows FY2024 GAAP EPS Guidance from $7.63-7.81 to $7.76-7.79 vs $7.73 Est

Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.35) by 2.86 percent. This is a 52.11 percent increase over losses of $(0.71) per share from the same period last year.

ACET

Adicet Bio Q3 EPS $(0.34) Beats $(0.35) Estimate

KVYO

Klaviyo Sees Q4 2024 Revenue $256M-$258M Vs $257.02M Estimate; Sees FY24 Revenue $923M-$925M Vs $915.6M Estimate

WOLF

Wolfspeed Sees Q2 Revenue $160M-$200M Vs $214.583M Est.; Adj. EPS $(1.14)-$(0.89) Vs $(0.90) Est.

Grand Canyon Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) narrows Q4 GAAP EPS guidance from $2.78-2.91 to $2.86-2.89 vs $2.85 analyst estimate..

Grand Canyon Education Narrows Q4 GAAP EPS Guidance from $2.78-2.91 to $2.86-2.89 vs $2.85 Est

ATRO

Astronics Sees FY24 Capital Expenditures $9M-$11M

SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) sees Q4 sales of $180.000 million-200.000 million vs $308.66 million estimate.

SEDG

SolarEdge Technologies Sees Q4 Sales $180.000M-200.000M vs $308.66M Est

Grand Canyon Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) narrows Q4 Adj EPS guidance from $2.84-2.97 to $2.92-2.95 vs $2.91 analyst estimate. Narrows Q4 sales outlook from $286.50 million-291.50 million to $289.00 million-290.00 million vs $289.30 million estimate.

Grand Canyon Education Narrows Q4 Adj EPS Guidance from $2.84-2.97 to $2.92-2.95 vs $2.91 Est; Narrows Q4 Sales Guidance from $286.50M-291.50M to $289.00M-290.00M vs $289.30M Est

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly earnings of $2.14 per share which beat the analyst consensus estimate of $2.12 by 0.94 percent. The company reported quarterly sales of $1.33 billion which met the analyst consensus estimate. This is a 1.04 percent decrease over sales of $1.34 billion the same period last year.

Steris Q2 2025 Sales $1.328B, Miss $1.33B Estimate

Management

NCR Voyex Announced The Appointment Of Darren Wilson as President, International.

NewtekOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWT#NASDAQ">NEWT</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.43 by 4.65 percent. The company reported quarterly sales of $62.832 million which beat the analyst consensus estimate of $61.398 million by 2.34 percent. This is a 23.26 percent increase over sales of $50.974 million the same period last year.

NEWT

NewtekOne Q3 2024 GAAP EPS $0.45 Beats $0.43 Estimate, Sales $62.832M Beat $61.398M Estimate

Astronics Sees FY24 Revenue $777M-$797M Vs $780.835M Est; Sees Q4 Revenue $190M-$210M

2024 OUTLOOK
The Company has maintained its previous midpoint full year comparable hotel guidance, which assumes a continued recovery in Maui and steady demand trends in the fourth quarter, despite the impacts of Hurricanes Helene and Milton. Operating profit margin and comparable hotel EBITDA margins in 2024 are expected to decline compared to 2023, impacted by the Maui wildfires and continued growth in wages, real estate taxes and insurance.
The Company's full year forecast comparable hotel set now includes the operations of The Ritz-Carlton O'ahu, Turtle Bay and 1 Hotel Central Park properties that were acquired in July 2024, and excludes The Don CeSar, which closed on September 25, 2024, as described above. The estimated impact to net income and Adjusted EBITDAre from the loss of business due to the hurricanes for 2024 is approximately $15&nbsp;million.
The impact from Maui operations is expected to be an approximate decline of 150 basis points in RevPAR and 110 basis points in Total RevPAR. When combined with the expected pre-wildfire Maui contribution, the total impact is estimated to be 220 basis points and 180 basis points, respectively. Net of the benefit of the business interruption gains relating to the wildfires received earlier this year, the year-over-year impact from Maui on net income and Adjusted EBITDAre for full year is expected to be a decline of $25 million, and on margins is expected to be a decline of approximately 20 basis points.
The Company anticipates its 2024 operating results as compared to 2023 will be approximately as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1">Current Full Year 2024 Guidance</td>
<td colspan="1">Current Full Year 2024 Guidance Change vs. 2023</td>
<td colspan="1">Previous Full Year 2024 Guidance Midpoint Change vs. 2023</td>
<td>Change in Full Year 2024 Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Comparable hotel Total RevPAR</td>
<td colspan="1">$353</td>
<td>1.2%</td>
<td>1.2%</td>
<td>0 bps</td>
</tr>
<tr>
<td>Comparable hotel RevPAR</td>
<td colspan="1">$215</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0 bps</td>
</tr>
<tr>
<td>Total revenues under GAAP (in millions)</td>
<td colspan="1">$5,637</td>
<td>6.1%</td>
<td>6.8%</td>
<td>(70) bps</td>
</tr>
<tr>
<td>Operating profit margin under GAAP</td>
<td>15.2%</td>
<td colspan="1">(40) bps</td>
<td colspan="1">0 bps</td>
<td>(40) bps</td>
</tr>
<tr>
<td>Comparable hotel EBITDA margin</td>
<td>29.0%</td>
<td colspan="1">(90) bps</td>
<td colspan="1">(90) bps</td>
<td>0 bps</td>
</tr>
</tbody>
</table>
</figure>
Based upon the above parameters, the Company estimates its 2024 guidance will be approximately as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1">Current Full Year 2024 Guidance</td>
<td colspan="1">Previous Full Year 2024 Guidance Midpoint</td>
<td colspan="1">Change in Full Year 2024 Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Net income (in millions)</td>
<td colspan="1">$687</td>
<td colspan="1">$712</td>
<td colspan="1">$(25)</td>
</tr>
<tr>
<td>Adjusted EBITDAre (in millions)</td>
<td colspan="1">$1,630</td>
<td colspan="1">$1,645</td>
<td colspan="1">$(15)</td>
</tr>
<tr>
<td>Diluted earnings per common share</td>
<td colspan="1">$0.96</td>
<td colspan="1">$0.99</td>
<td colspan="1">$(0.03)</td>
</tr>
<tr>
<td>NAREIT and Adjusted FFO per diluted share</td>
<td colspan="1">$1.92</td>
<td colspan="1">$1.94</td>
<td colspan="1">$(0.02)</td>
</tr>
</tbody>
</table>
</figure>
See the 2024 Forecast Schedules and the Notes to Financial Information for items that may affect forecast results.

Host Hotels & Resorts Sees FY24 Adj. FFO Per Share $192-$1.94; Diluted EPS $0.96-$0.99 Vs $0.95 Est.; Revenue $5.637B Vs $5.62B Est.

In a report released on May 14, Jack Allen from Robert W. Baird maintained a Buy rating on MiNK Therapeutics (INKT – Research Report), with a price...

MiNK Therapeutics Poised for Growth with Strong Trial Enrollment and New Investments: A Buy Rating from Jack Allen

MiNK Therapeutics regains compliance with Nasdaq

MiNK Therapeutics GAAP EPS of -$0.07 beats by $0.02

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on MiNK Therapeutics (INKT – Research Report), with a price t...

MiNK Therapeutics' Promising Clinical Trials and Strategic Expansion Set to Enhance Stock Value

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MiNK Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/inkt-stock-quote/">INKT</a>) just reported results for the second quarter of 2024.<ul><li>MiNK Therapeutics reported earnings per share of -7 cents. This was above the analyst estimate for EPS of -10 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/inkt-stock-earnings-mink-therapeutics-for-q2-of-2024/">INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript

MiNK Therapeutics files to sell 4.64M shares of common stock  for holders

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Black Diamond Therapeutics (BDTX – Research Report),...

Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), MiNK Therapeutics (INKT)

MiNK Therapeutics (INKT) announced the appointment of Dr. Robert Kadlec to its Board of Directors. Kadlec recently served as the U.S. Senate-confir...

MiNK Therapeutics appoints Robert Kadlec to board of directors

MiNK Therapeutics ( ($INKT) ) has issued an announcement. MiNK Therapeutics Inc. has appointed Dr. Robert Kadlec as a Class II director on its Boar...

Comments

MiNK Therapeutics

Notizie

Ultime notizie per MiNK Therapeutics (NASDAQ:INKT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO